Dr.M.shafiee Department of internal medicine Shiraz university of medical sciences
mean home BP>135/85 mean ABPM>130/80 Mean interdialytic BP at mead week >140/90
Dialysis Unit: During, Before, or After Home BP ABPM
Predialysis SBP overestimated mean SBP by an average of 10 mm Hg Postdialysis SBP underestimated mean SBP by an average of 7 mm Hg BP readings over a period of 1 to 2 weeks rather than isolated readings should be used
Sodium and volume overload. Sympathetic nervous system activity Inappropriate renin secretion. Alteration in endothelin and nitric oxide. Erythropoietin therapy. Hyperparathyroidism. Others: Uremic toxins, Nocturnal hypoxemia and sleep disturbances Essential Hypertension before ESRD
Hypervolemia is the major factor Positive Sodium balance Increases intake and decreased excretion Achieving DW will control 60% of cases of HTN
Management
Step 1: Lifestyle modifications and control of volume status with lifestyle modifications. Step 2: Control of volume status with dialysis. Step 3: Administration of antihypertensive drugs
Restriction of Na and water and fluid Restriction of salt to maximum 5gr per day Exercise
Control of volume status Limit interdialytic weight gain a 2.5 kg is associated with a significant increase in BP Achieve dry weight Frequent dialysis & Longer dialysis time
Criteria to determining DW: No marked fall in BP during dialysis. No hypertension (predialysis BP at the beginning of the week <140/90 mm Hg). No peripheral edema. No pulmonary congestion on chest X-ray. Cardiothoracic ratio ≤50% (≤53% in females).
Na restriction and dry weight can control BP in % of patients The absence of edema dose not exclude the hypervolemia
Antihypertensive drugs are indicated in patients in whom hypertension persist, despite seemingly adequate volume control All classes of antihypertensive drugs can be used in dialysis patients, with the sole exception of diuretics The selection of antihypertensive agents is frequently dictated by the presence of comorbid conditions
ARBs and ACE are the preferable first line of antihypertensive drugs They are well tolerated and are particularly effective in patients with a history of heart failure due to systolic dysfunction and may induce a more rapid regression of LVH They may aggravate anemia by reducing the action of erythropoietin
They are indicated in patients who have had a recent MI or suffer from angina pectoris Potential side effects include CNS depression Bradycardia, altered lipid profiles,hyperkalemia altered response to hypoglycemia and bronchospasm
They are effective and well tolerated in dialysis patients In this group Amlodipin can decrease mortality
Methyl doppa and clonidine are in this group But due to infavorable side effects use of them are limitted
Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive agents of different classes
The use of non steroidal anti-inflammatory drugs Renovascular hypertension Increasing cysts in polysystic kidney disease Compliance
If a treatable cause cannot be found,minoxidil in combination with beta blocker may be effective Spironolactone in Hemodialysis Patients mg post dialysis Risk of hyperkalemia Improve EF and Improve BP control Large studies are done
Renal sympathetic nerve ablation Bilateral nephrectomy May be considered in the rare, noncompliant individual with life-threatening hypertension unable to be controlled with any dialysis modality
5-15% Mechanism Endothelial dysfunction Activation of renin angiotensin system Sodium level Activation of systematic nervous system Extracellular volume overload
The most important treatment is adequate sodium and water removal and reducing sympathetic hyperactivity. Changing to non-dialyzable antihypertensive medications Altering the dialysis prescription
ACEI or αblocker at the time of hypertension or befor hemodialysis Carvedilol, which blocks endothelin-1 release, appears to be effective in this setting
Thank you